Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment and Forecast

Description

This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the CKD-HPT, HP and HK market through 2034.

There will be an overall increase in the diagnosed prevalent cases of CKD- HPT, HP and HK in the 7MM across the forecast period.
Across the 7MM, the mainstay treatment for HPT, HP, and HK involves phosphate binders, calcimimetics, and potassium binders
Significant clinical and environmental unmet needs remain in the CKD- HPT, HP and HK market.
The Combined sales for CKD-HPT, HP, and HK are expected to grow modestly over the forecast period, from $2.6 billion in 2024 to $4.0 billion by 2034, at a compound annual growth rate (CAGR) of 4.4%.

Overview of CKD, including epidemiology, symptoms, diagnosis, and disease management.
Annualized CKD- HPT, HP and HK therapeutics market revenue in 7MM (US, 5EU, and Japan), annual cost of therapy and treatment usage pattern in 2024 and forecast for 10 years to 2034.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CKD- HPT, HP and HK therapeutics market.
Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for CKD- HPT, HP and HK treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the 7MM CKD- HPT, HP and HK therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the CKD- HPT, HP and HK therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CKD- HPT, HP and HK therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Product Code: GDHCOA057

4.1. Diagnosed Prevalent Cases of CKD
4.2. Age-Specific Trends in Diagnosed Prevalent Cases of CKD
4.3. Sex-Specific Diagnosed Prevalent Cases of CKD
4.4. Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
4.5. Diagnosed Prevalent Cases of CKD with HPT
4.6. Diagnosed Prevalent Cases of CKD with HP
4.7. Diagnosed Prevalent Cases of CKD with HK
4.8. Total Prevalent Cases of CKD
4.9. Total Prevalent Cases of CKD by Stage
4.10. Sources and Methodology: Total Prevalent Cases of CKD by Stage
4.11. Sources and Methodology: Diagnosed Prevalent Cases of CKD
4.12. Sources and Methodology: Diagnosed Prevalent Cases of CKD by Stage
4.13. Sources and Methodology: Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
4.14. Sources and Methodology: Diagnosed Prevalent Cases of CKD with HPT, HP, and HK Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases
4.15. Sources and Methodology: Total Prevalent Cases of CKD
4.16. Sources and Methodology - Diagnosed Prevalent Cases of CKD with HPT Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases
4.17. Sources and Methodology - Diagnosed Prevalent Cases of CKD with HP Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases
4.18. Sources and Methodology - Diagnosed Prevalent Cases of CKD with HK Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases